APM
PLRX icon

Avidity Partners Management’s Pliant Therapeutics PLRX Stock Holding History

Avidity Partners Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-916,600
Closed -$16.6M – 98
2023
Q2 		$16.6M Sell
916,600
-1,748,400
-66% -$41.4M 0.58% 58
2023
Q1 		$70.9M Buy
2,665,000
+424,600
+19% +$12.1M 2.35% 16
2022
Q4 		$43.3M Buy
2,240,400
+259,300
+13% +$5.42M 0.94% 34
2022
Q3 		$41.4M Buy
+1,981,100
New +$37.9M 0.84% 41

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Avidity Partners Management's PLRX Position: Q3 2023 in Review

Avidity Partners Management sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 916,600 shares — an estimated $16.6M sold.

Avidity Partners Management first reported a position in PLRX in Q3 2022 and held it in 4 quarters. The position peaked at $70.9M in Q1 2023. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • Avidity Partners Management reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Avidity Partners Management sold 916,600 Pliant Therapeutics shares in Q3 2023, an estimated $16.6M.
  • Avidity Partners Management first reported a position in Pliant Therapeutics in Q3 2022 and held it in 4 quarters.
  • Avidity Partners Management's Pliant Therapeutics position peaked at $70.9M in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Avidity Partners Management's 13F filing for Q3 2023, filed 14 Nov 2023.